semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  HPV Penn State Health Patient Has an intact cervix Found to have abnormal findings on Pap/HPV test that requires a colposcopy Speaks, read, or writes well in English or Spanish  Pregnant Cognitively impaired Incarcerated Complete hysterectomy History of cervical treatment for abnormal Pap/HPV test (i.e. cryotherapy, loop electrosurgical excision procedure (LEEP))
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-65.0,  HPV Age 30-65 Years Penn State Health, Family and Community Medicine, patient attending a well-woman visit Able to collect the sample within two weeks of visit Female Intact cervix Speaks, reads, or writes in English  Pregnancy Cognitively Impaired Incarcerated Complete hysterectomy History of cervical treatment for abnormal Pap/HPV test (cryotherapy, LEEP)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 25.0-55.0,  HPV Females aged ≥25 and ≤55 years of age at screening Persistent hrHPV infection defined as a documented cervical infection with hrHPV type(s) in the 6 to 18 months prior to screening and confirmed at screening (participants in the main and expansion phases only). Participants in the lead-in phase are only required to have the screening result Low-grade cervical lesion (CIN1 or HPV-related change only) confirmed by histology and/or cytology report within the 1 year prior to screening Not pregnant or breast feeding and one of the following Of non-childbearing potential (i.e. women who have had a hysterectomy or tubal ligation or are postmenopausal, as defined by no menses for at least 12 months and without an alternative medical cause) Of childbearing potential but agrees to practice highly effective contraception for 4 weeks prior to administration of the first dose of study vaccine and throughout the study until 8 weeks after administration of the second dose. Highly effective methods of contraception one or more of the following Male partner who is sterile (medically effective vasectomy) prior to the female participant's entry into the study and is the sole sexual partner for the female participant Hormonal (oral, intravaginal, transdermal, implantable or injectable). Progestogen-only hormonal contraceptives without inhibition of ovulation are not considered to be highly effective An intrauterine hormone-releasing system An intrauterine device  Presence of any significant acute or chronic, uncontrolled medical (or psychiatric) illness, including blood dyscrasias Immunosuppression as a result of underlying illness or treatment including Use of high dose corticosteroids ( >10 mg/day prednisone or equivalent) for ≥7 days (inhaled, otic and ophthalmic corticosteroids are permitted) Primary immune deficiency disease Use of synthetic or biologic disease-modifying antirheumatic drugs History of bone marrow or solid organ transplant History of any other clinically significant autoimmune or immunosuppressive disease Positive diagnostic tests (for human immunodeficiency virus, hepatitis B or hepatitis C) indicating chronic infection Evidence of high-grade cervical lesions by colposcopy or by Papanicolaou (Pap) smear test in the 1 year prior to screening Any history of anaphylaxis in reaction to vaccination or history of allergic reactions likely to be exacerbated by any component of the vaccine
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-55.0,  Cervical Cancer gender: female 2. age: 30-55 3. no current diagnosis of cervical cancer, and 4. have not participated in cervical cancer screening within the past 3 years
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Coxarthrosis All patient who underwent THA via DAA by a single surgeon who routinely documents the distance from the shoulder of the stem to the upper border of the EO tendon  Distance not noted No radiographs available
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer All subjects Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Confirmed HPV 16+ (human papilloma virus 16 positive) genotype testing of cancer Disease-free for ≥ 2 years from other curatively treated cancers, with protocol-defined exceptions Evaluated by cardiologist and/or neurologist if protocol-defined cardiac or neurological event within the last 6 months. HPV 16+ Oropharynx Cancer (Arm 1 Cohorts 1 and 2) Newly diagnosed, squamous cell carcinoma or undifferentiated carcinoma of the oropharynx, determined to be resectable AJCC v8.0 Tumor, Node, Metastasis (TNM) stage I-III, cT1 T3, and cervical nodes N1-N3 based on clinical or radiographic with no evidence of distant metastases No prior radiation above the clavicles Must have acceptable renal and hepatic function as defined per protocol  All subjects Treatment with any systemic anticancer therapy within 3 years (unless agreed otherwise between the Sponsor and the Investigator) Treatment with any chronic immunosuppressive medication within 6 months (unless agreed otherwise between the Sponsor and Investigator) Uncontrolled diabetes, uncontrolled infection despite antibiotics or uncontrolled hypertension Live vaccine within 28 days (unless agreed otherwise between Sponsor and Investigator) Known diagnosis of acquired immunodeficiency syndrome (AIDS) Positive Hepatitis B or Hepatitis C tests indicating acute or chronic infection Intercurrent illness likely to interfere with protocol therapy Female subjects who are pregnant or breastfeeding Female subjects of childbearing potential who do not agree to the use of highly effective contraception per protocol
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Endothelial Dysfunction We recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital  History of Coronary artery disease History of Peripheral Arterial Disease History of Heart failure History of Stroke hepatic failure renal failure active neoplasia poorly controlled DM, defined as Hba1C>7%
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Participant Must Have histologically confirmed invasive ER+, HER2 breast carcinoma Be willing and able to provide pre and on-treatment tumor samples Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale Have adequate organ function Be able to swallow capsules  Participant Must Not Have bilateral invasive breast cancer Have metastatic breast cancer Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer Have had prior radiotherapy to the ipsilateral chest wall for any malignancy Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s) Be pregnant or breastfeeding
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Femur Fracture -proximal femur fracture  pregnancy and lactation history of opiate addiction traumatic brain injury acute cerebrovascular accident chronic heart failure (New York Heart Association Functional Classification, NYHA, class III-IV) respiratory failure renal failure with decreased creatinine clearance less than 30 ml / min / 1.73 m2 hepatic insufficiency class C according to Child-Pugh)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-45.0,  Tubal Ligation Women aged from 30-40 year Woman subjected to tubal ligation Women 12 month postpartum Non lactating women Nomedical disorders  contraindication for Levonorgestrel-releasing Intrauterine System Women with any uterine or ovarian pathology women refuse to participate
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Pleural Effusion, Malignant Prognosis Patients presented with pleural effusion Patients who undergo thoracentesis and fluid analysis for diagnosis and management  Patients who refuse to be enrolled
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 16.0-39.0,  Papillomavirus Vaccines Papillomavirus Infections Japanese women who seek cervical cancer screening or gynecological consultations Women with benign conditions 39 year-old Women must be sexually experienced, as defined by sexual contact (oral-genital or genital-genital) with at least one male or female partner  Women with STDs Women with premalignant lesions of the cervicovaginal tract Women suffering from any cancer Women with any severe acute or chronic disease, and/or psychological problems
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cervical Cancer Head and Neck Cancer Anal Cancer Signed written informed consent obtained prior to study procedures Patients ≥18 years with an ECOG 0 or 1 Histologically confirmed diagnosis by the local laboratory of persistent, recurrent, or metastatic, unresectable cervical cancer (squamous, adeno, or adenosquamous histology), HNSCC, or squamous cell cancer of the anal canal that is not amenable to curative therapy All patients must have experienced disease progression following platinum-based or mitomycin C-based chemotherapy administered in the persistent, recurrent, or metastatic setting All patients with programmed death-ligand 1 (PD-L1) positive cervical cancer and those with HNSCC must have received or have been determined to be ineligible for immunotherapy with a PD-1 or PD-L1 inhibitor All patients with cervical cancer will have received or have been determined to be ineligible for bevacizumab Confirmation of HLA-A*02:01 positive status by central testing In patients with cervical cancer or HNSCC, confirmation of HPV 16 within the tumor either from historical pathology result (using an FDA-approved HPV testing method, patients with cervical cancer only) or based on central laboratory analysis of a tumor sample. Patients with anal cancer will not be required to have prospective determination of HPV 16 positive status prior to enrollment Disease must be measurable per Response Evaluation The shorter of 28 days or 5 half-lives must have elapsed since the completion of prior therapy, before initiation of study treatment Adequate Organ Function as Defined by the protocol  Patient has central nervous system (CNS) involvement. If the patient fulfills the following 3 she/he is eligible for the trial after consultation with the Sponsor Medical Monitor Completed prior therapy for CNS metastases (radiation and/or surgery) CNS tumor(s) is clinically stable at the time of enrollment Patient does not require corticosteroid or antiepileptic therapy for management of CNS metastases Known hypersensitivity to any component of study treatment or excipients Positive antibody screen using institution's standard type and screen test Clinically significant, active and uncontrolled infection, including human immunodeficiency virus (HIV), Hepatitis B virus (HBV), or Hepatitis C virus (HCV)
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 30.0-64.0,  Uterine Cervical Neoplasm Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases Uterine Diseases Cervical Cancer Cervical Dysplasia Human Papilloma Virus HPV-Related Cervical Carcinoma HPV Infection HPV-Related Malignancy Currently enrolled at Kaiser Permanente Washington Female sex years to 64 years of age An intact cervix Has a primary care provider at Kaiser Permanente Washington  Anyone flagged by the delivery system as being on a non-routine screening schedule Previously randomized to the intervention arm of the HOME trial or invited to the PATH study (Participants from the PATH study and individuals randomized to the intervention arm in the HOME Study are excluded from STEP because their prior in a STEP-related research study could influence their screening uptake and affect the outcome of this trial.) On "do not contact list" for research studies Currently pregnant or had a pregnancy-related procedure within prior 3 months Language interpreter needed
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Cervical Cancer Age Limits: more than 18Y Histologically confirmed squamous cell carcinoma, FIGO stage IB-IVA planned for radical radiochemotherapy Eastern Cooperative Oncology Group (ECOG) performance status 0,1,2  Patients who have received any anticancer treatment for their cervical cancer. Eastern Cooperative Oncology Group (ECOG) performance status > 2 Other cervical cancer tumor histologies (e.g. small cell, serous) Contraindications to 18FDG PET-CT Contraindication to radiochemotherapy Known pregnancy or lactating
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Thoracic Cancer Abdominal Cancer Patients must be willing and capable to provide informed consent to participate in the protocol. 2. Patient with presumed pulmonary function capable of holding breath for at least 30 seconds later to be confirmed. 3. All men, as well as women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, and until study imaging is complete. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. 3.1 A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following Has not undergone a hysterectomy or bilateral oophorectomy; or Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months). 3.2 Patients must be compliant to all required pretreatment evaluations  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus 2. Patients are not compliant to all required pretreatment evaluations
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Bladder Cancer Radical Cystectomy Muscle-invasive Bladder Cancer Patient undergoing radical cystectomy since September 2016 December 2020 Development of bladder cancer confirmed histologically Written informed consent  • Lack of clinical and prognostic data on selected patients
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Uterine Cervical Neoplasms Patients who have signed an approved Informed Consent 5≤BMI<28 Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage IA2, stage IB1, stage IB2, or stage IIA1 disease(FIGO 2018) Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1 Patients undergoing the Non-Fertility-Sparing surgery Patients undergoing abdominal surgery  The life expectancy of the patient is less than 6 months Patients with serious medical diseases Patients with contraindications to surgery or anesthesia Preoperative imaging studies suggest metastasis to pelvic lymph nodes or para-aortic lymph nodes Patient asks to preserve fertility The patient requested direct radiation therapy Patients with adjuvant radiotherapy or chemotherapy before surgery Patients judged by the investigator to be unsuitable to participate in this trial
Patient description: The patient is a 37-year-old woman who came to the clinic for a routine Pap smear. The test revealed stage 1B of cervical cancer. The patient tested positive for HPV 16. She has three sexual partners and four children. She underwent tubal ligation. She smokes 30 packs/year and drinks alcohol frequently. She is otherwise healthy. She was offered a radical hysterectomy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hip Arthropathy Clinical diagnosis of primary hip osteoarthritis(OA), fracture of femoral neck (FFN),or secondary hip osteoarthritis due to developmental dysplasia of the hip (DDH), hip avascular necrosis (AVN), rheumatoid arthritis (RA), ankylosing spondylitis (AS), and coxa plana  Severe vascular diseases of the lower extremity Neuromuscular diseases Infectious diseases Severe dysfunctions of major organs Severe neurosensory deficiencies caused by spinal diseases Unable to receive CT/MRI scans